Most prostate cancers are androgen-sensitive malignancies whose growths depend on the
transcriptional activity of the androgen receptor (AR). In the 1940s, Charles Huggins …

The possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC)
have dramatically increased during the last years. The old backbone, which androgen …

Background STAMPEDE has previously reported that the use of upfront docetaxel improved
overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long …

Background The efficacy and safety of cabazitaxel, as compared with an androgen-signaling–
targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration …

Background In the phase 3 TITAN study, the addition of apalutamide to androgen
deprivation therapy (ADT) significantly improved the primary endpoints of overall survival …

Objectives To report the outcomes of stereotactic ablative body radiotherapy (SABR) in men
with oligometastatic prostate cancer (PC a) diagnosed on prostate‐specific membrane …

The treatment of genitourinary malignancies has dramatically evolved over recent years.
Renal cell carcinoma, urothelial carcinoma of the bladder, and prostate adenocarcinoma are …

Enzalutamide and apalutamide are two androgen receptor inhibitors approved for the
treatment of castration-resistant prostate cancer (CRPC) and nonmetastatic castration …

The treatment landscape of advanced prostate cancer continues to evolve rapidly, with
newer and more active drugs being used in earlier phases of the disease based on …

Androgen receptor (AR) inhibitors represent the mainstay of prostate cancer treatment. In a
genome-wide CRISPR-Cas9 screen using LNCaP prostate cancer cells, loss of co …